Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Nektar Therapeutics (NASDAQ: NKTR) closed at $1.00 in the last session, down -0.99% from day before closing price of $1.01. In other words, the price has decreased by -$0.99 from its previous closing price. On the day, 1.03 million shares were traded. NKTR stock price reached its highest trading level at $1.05 during the session, while it also had its lowest trading level at $1.0.
Ratios:
We take a closer look at NKTR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 4.22 whereas as Long-Term Debt/Eq ratio is at 3.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 10, 2024, initiated with a Buy rating and assigned the stock a target price of $6.50.
On November 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Zalevsky Jonathan sold 7,785 shares for $1.01 per share. The transaction valued at 7,863 led to the insider holds 243,019 shares of the business.
Wilson Mark Andrew sold 6,407 shares of NKTR for $6,471 on Nov 19 ’24. The Chief Legal Officer now owns 218,856 shares after completing the transaction at $1.01 per share. On Nov 19 ’24, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 16,278 shares for $1.01 each. As a result, the insider received 16,441 and left with 832,080 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 186303008 and an Enterprise Value of 146054288. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.00 while its Price-to-Book (P/B) ratio in mrq is 3.77. Its current Enterprise Value per Revenue stands at 1.568 whereas that against EBITDA is -1.122.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -17.49%, while the 200-Day Moving Average is calculated to be -20.81%.
Shares Statistics:
According to the various share statistics, NKTR traded on average about 1.71M shares per day over the past 3-months and 2650370 shares per day over the past 10 days. A total of 184.46M shares are outstanding, with a floating share count of 178.22M. Insiders hold about 3.38% of the company’s shares, while institutions hold 74.38% stake in the company. Shares short for NKTR as of 1732838400 were 4440183 with a Short Ratio of 2.60, compared to 1730332800 on 5226179. Therefore, it implies a Short% of Shares Outstanding of 4440183 and a Short% of Float of 3.08.
